Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

DOI10.1111/J.0006-341X.2000.01177.XzbMATH Open1060.62547WikidataQ73326314 ScholiaQ73326314MaRDI QIDQ4670477FDOQ4670477

Authors: Ying Kuen Cheung, Rick Chappell 

Publication date: 22 April 2005

Published in: Biometrics (Search for Journal in Brave)

Recommendations

• Sequential designs for dose escalation studies in oncology
• Optimal sequential designs in phase I studies
• Sequential designs for ordinal phase I clinical trials
• scientific article; zbMATH DE number 3856244
• Designs for phase II trials with trade-of between efficacy and toxicity
• Designs for Group Sequential Phase II Clinical Trials
• Sequential experimentation in clinical trials. Design and analysis

zbMATH Keywords

continual reassessment methodtime-to-eventphase I trialdose limitinglate-onset toxicitieslikelihood-based design

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)

Cites Work

• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
• A Random Walk Rule for Phase I Clinical Trials
• Consistency of continual reassessment method under model misspecification
• Continual Reassessment Method: A Likelihood Approach

Cited In (53)

• Application of the patient-reported outcomes continual reassessment method to a phase I study of radiotherapy in endometrial cancer
• Impact of different model structure and prior distribution in continual reassessment method
• Bayesian models and decision algorithms for complex early phase clinical trials
• Joint modelling of recurrence and progression of adenomas: a latent variable approach
• A simple technique to evaluate model sensitivity in the continual reassessment method
• On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance
• Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
• A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
• TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy
• Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
• Ethical issues in oncology biostatistics
• The adaptive accelerated biased coin design for phase I clinical trials
• Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial
• Unifying CRM and EWOC designs for phase I cancer clinical trials
• Dynamic Comparison of Kaplan–Meier Proportions: Monitoring a Randomized Clinical Trial with a Long‐Term Binary Endpoint
• DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses
• A simulation-free approach to assessing the performance of the continual reassessment method
• Fractional accumulative calibration-free odds (f-aCFO) design for delayed toxicity in phase I clinical trials
• Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
• Cumulative cohort design for dose-finding
• Risk-group-specific dose finding based on an average toxicity score
• CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome
• Early completion of phase I cancer clinical trials with Bayesian optimal interval design
• Seamless phase I/II design for novel anticancer agents with competing disease progression
• Dose finding with escalation with overdose control (EWOC) in cancer clinical trials
• A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules
• Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
• Extending the continual reassessment method to accommodate step-up dosing in phase I trials
• Dose finding studies for therapies with late-onset toxicities: a comparison study of designs
• Surv-CRM-12: a Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression
• Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
• A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
• A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering
• SEQUENTIAL METHODS IN CLINICAL TRIALS*
• A weighted zero-inflated Poisson model for estimation of recurrence of adenomas
• Adaptive clinical trial designs for phase I cancer studies
• Monitoring the rates of composite events with censored data in phase II clinical trials
• Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment
• Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
• Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials
• Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
• Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials
• A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients
• Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
• Target toxicity design for phase I dose-finding
• Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
• Monitoring late-onset toxicities in phase I trials using predicted risks
• Handbook of statistics in clinical oncology
• Stochastic approximation and modern model-based designs for dose-finding clinical trials
• Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials

This page was built for publication: Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4670477)